Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01215643




Registration number
NCT01215643
Ethics application status
Date submitted
5/10/2010
Date registered
6/10/2010
Date last updated
30/08/2016

Titles & IDs
Public title
Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants
Scientific title
A Multicenter, Randomized, Open Label, Parallel-group Phase IIB Study on the Efficacy and Safety of Oral Regimens of DEB025 Alone or in Combination With Ribavirin Versus Standard of Care (Peg-IFNa2a Plus Ribavirin) in Treatment-naïve Hepatitis C Genotype 2 and 3 Patients
Secondary ID [1] 0 0
2010-020034-26
Secondary ID [2] 0 0
CDEB025A2211
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hepatitis C 0 0
Chronic Pain 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Neurological 0 0 0 0
Other neurological disorders
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Alisporivir
Treatment: Drugs - Peginterferon alfa-2a
Treatment: Drugs - Ribavirin

Experimental: ALV 1000 mg - Alisporivir (ALV) 600 mg twice daily (BID) for 1 week, followed by ALV 1000 mg once daily (QD) during Weeks 2 to 24.

Experimental: ALV 600 mg+RBV - Alisporivir (ALV) 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with ribavirin (RBV) during Weeks 2 to 24.

Experimental: ALV 800 mg+RBV - Alisporivir (ALV) 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.

Experimental: ALV 600 mg+PEG - Alisporivir (ALV) 600 mg BID with Peginterferon alfa-2a (PEG) for 1 week, followed by ALV 600 mg QD with PEG once weekly during Weeks 2 to 24.

Active comparator: PEG+RBV - Peginterferon alfa-2a (PEG) and RBV during Weeks 1 to 24.


Treatment: Drugs: Alisporivir
ALV 200 mg soft gel capsules administered orally

Treatment: Drugs: Peginterferon alfa-2a
PEG 180 µg administered via subcutaneous (s.c.) injection once weekly

Treatment: Drugs: Ribavirin
RBV 400 mg (2 x 200 mg tablets) administered orally twice daily (BID)
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants With Rapid Viral Response (RVR) After 4 Weeks of Treatment < the Limit of Quantification (RVR4LOQ)
Timepoint [1] 0 0
after 4 weeks of treatment
Secondary outcome [1] 0 0
Percentage of Participants With RVR After 4 Weeks of Treatment < the Limit of Detection (RVR4LOD)
Timepoint [1] 0 0
after 4 weeks of treatment
Secondary outcome [2] 0 0
Percentage of Participants With RVR4LOQ and RVR4LOD (Genotype 2)
Timepoint [2] 0 0
after 4 weeks of treatment
Secondary outcome [3] 0 0
Percentage of Participants With RVR4LOQ and RVR4LOD (Genotype 3)
Timepoint [3] 0 0
after 4 weeks of treatment
Secondary outcome [4] 0 0
Percentage of Participants With Complete Early Viral Response (cEVR) After 12 Weeks of Treatment (cEVR12LOQ and cEVR12LOD)
Timepoint [4] 0 0
after 12 weeks of treatment
Secondary outcome [5] 0 0
Percentage of Participants With cEVR12LOQ and cEVR12LOD (Genotype 2)
Timepoint [5] 0 0
after 12 weeks of treatment
Secondary outcome [6] 0 0
Percentage of Participants With cEVR12LOQ and cEVR12LOD (Genotype 3)
Timepoint [6] 0 0
after 12 weeks of treatment
Secondary outcome [7] 0 0
Percentage of Participants With End of Treatment Response (ETR) Within 24 Weeks (ETR24LOQ and ETR24LOD)
Timepoint [7] 0 0
at end of treatment, within 24 weeks
Secondary outcome [8] 0 0
Percentage of Participants With ETR24LOQ and ETR24LOD (Genotype 2)
Timepoint [8] 0 0
at end of treatment, within 24 weeks
Secondary outcome [9] 0 0
Percentage of Participants With ETR24LOQ and ETR24LOD (Genotype 3)
Timepoint [9] 0 0
at end of treatment, within 24 weeks
Secondary outcome [10] 0 0
Percentage of Participants With RVR Who Achieved Sustained Viral Response (SVR) 12 Weeks After the End of Treatment (SVR12LOQ and SVR12LOD)
Timepoint [10] 0 0
12 weeks after the end of treatment
Secondary outcome [11] 0 0
Percentage of Participants With RVR Who Achieved SVR12LOQ and SVR12LOD (Genotype 2)
Timepoint [11] 0 0
12 weeks after the end of treatment
Secondary outcome [12] 0 0
Percentage of Participants With RVR Who Achieved SVR12LOQ and SVR12LOD (Genotype 3)
Timepoint [12] 0 0
12 weeks after the end of treatment
Secondary outcome [13] 0 0
Percentage of Participants With RVR Who Achieved SVR at 24 Weeks After the End of Treatment (SVR24LOQ and SVR24LOD)
Timepoint [13] 0 0
24 weeks after the end of treatment
Secondary outcome [14] 0 0
Percentage of Participants With RVR Who Achieved SVR24LOQ and SVR24LOD (Genotype 2)
Timepoint [14] 0 0
24 weeks after the end of treatment
Secondary outcome [15] 0 0
Percentage of Participants With RVR Who Achieved SVR24LOQ and SVR24LOD (Genotype 3)
Timepoint [15] 0 0
24 weeks after the end of treatment
Secondary outcome [16] 0 0
Percentage of Participants With On-treatment Viral Breakthrough
Timepoint [16] 0 0
within 24 weeks of treatment
Secondary outcome [17] 0 0
Percentage of Participants With Viral Relapse
Timepoint [17] 0 0
within 24 weeks after the end of treatment

Eligibility
Key inclusion criteria
Inclusion criteria:

* Chronic hepatitis C viral infection
* Plasma HCV RNA level lower limit = 10,000 IU/ml assessed by quantitative polymerase chain reaction (qPCR) or equivalent at screening (no upper limit)
* HCV genotype 2 or 3
* No previous treatment for hepatitis C infection
Minimum age
18 Years
Maximum age
70 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria:

* Evidence of cirrhosis at the time of screening
* Evidence of hepatocellular carcinoma at the time of screening
* Any other cause of relevant liver disease other than HCV
* Alanine aminotransferase (ALT) = 10 times upper limit of normal (ULN)
* Other protocol-defined inclusion/exclusion criteria may apply

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/10/2010
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/05/2012
Sample size
Target
Accrual to date
Final
340
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
Novartis Investigative Site - Kingswood
Recruitment hospital [2] 0 0
Novartis Investigative Site - Kogarah
Recruitment hospital [3] 0 0
Novartis Investigative Site - Westmead
Recruitment hospital [4] 0 0
Novartis Investigative Center - Greenslopes
Recruitment hospital [5] 0 0
Novartis Investigative Site - Clayton
Recruitment hospital [6] 0 0
Novartis Investigative Site - Fitzroy
Recruitment postcode(s) [1] 0 0
2747 - Kingswood
Recruitment postcode(s) [2] 0 0
2217 - Kogarah
Recruitment postcode(s) [3] 0 0
2145 - Westmead
Recruitment postcode(s) [4] 0 0
4120 - Greenslopes
Recruitment postcode(s) [5] 0 0
3168 - Clayton
Recruitment postcode(s) [6] 0 0
3065 - Fitzroy
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Hawaii
Country [3] 0 0
United States of America
State/province [3] 0 0
Kansas
Country [4] 0 0
United States of America
State/province [4] 0 0
Massachusetts
Country [5] 0 0
United States of America
State/province [5] 0 0
Missouri
Country [6] 0 0
United States of America
State/province [6] 0 0
New Hampshire
Country [7] 0 0
United States of America
State/province [7] 0 0
New York
Country [8] 0 0
United States of America
State/province [8] 0 0
Texas
Country [9] 0 0
Belgium
State/province [9] 0 0
Bruxelles
Country [10] 0 0
Belgium
State/province [10] 0 0
Gent
Country [11] 0 0
Belgium
State/province [11] 0 0
Leuven
Country [12] 0 0
Canada
State/province [12] 0 0
British Columbia
Country [13] 0 0
Canada
State/province [13] 0 0
Ontario
Country [14] 0 0
France
State/province [14] 0 0
Clichy Cedex
Country [15] 0 0
France
State/province [15] 0 0
Creteil
Country [16] 0 0
France
State/province [16] 0 0
Marseille
Country [17] 0 0
France
State/province [17] 0 0
Paris
Country [18] 0 0
Germany
State/province [18] 0 0
Berlin
Country [19] 0 0
Germany
State/province [19] 0 0
Frankfurt
Country [20] 0 0
Germany
State/province [20] 0 0
Freiburg
Country [21] 0 0
Germany
State/province [21] 0 0
Hannover
Country [22] 0 0
Germany
State/province [22] 0 0
Leipzig
Country [23] 0 0
India
State/province [23] 0 0
Kerala
Country [24] 0 0
India
State/province [24] 0 0
Maharashtra
Country [25] 0 0
India
State/province [25] 0 0
Punjab
Country [26] 0 0
India
State/province [26] 0 0
Uttar Pradesh
Country [27] 0 0
India
State/province [27] 0 0
Guwahati
Country [28] 0 0
India
State/province [28] 0 0
Haryana
Country [29] 0 0
India
State/province [29] 0 0
Hyderabad - Andhra Pradesh
Country [30] 0 0
India
State/province [30] 0 0
Mumbai
Country [31] 0 0
India
State/province [31] 0 0
New Delhi
Country [32] 0 0
Italy
State/province [32] 0 0
Bologna
Country [33] 0 0
Italy
State/province [33] 0 0
Brescia
Country [34] 0 0
Italy
State/province [34] 0 0
Pavia
Country [35] 0 0
Italy
State/province [35] 0 0
Roma
Country [36] 0 0
Italy
State/province [36] 0 0
Torino
Country [37] 0 0
Korea, Republic of
State/province [37] 0 0
Pusan
Country [38] 0 0
Korea, Republic of
State/province [38] 0 0
Seoul
Country [39] 0 0
Poland
State/province [39] 0 0
Bialystok
Country [40] 0 0
Poland
State/province [40] 0 0
Lódz
Country [41] 0 0
Poland
State/province [41] 0 0
Warsaw
Country [42] 0 0
Puerto Rico
State/province [42] 0 0
San Juan
Country [43] 0 0
Taiwan
State/province [43] 0 0
Kaohsiung
Country [44] 0 0
Taiwan
State/province [44] 0 0
Niaosong Township
Country [45] 0 0
Taiwan
State/province [45] 0 0
Taichung
Country [46] 0 0
Taiwan
State/province [46] 0 0
Taipei
Country [47] 0 0
Taiwan
State/province [47] 0 0
Yun-Lin
Country [48] 0 0
Thailand
State/province [48] 0 0
Bangkok
Country [49] 0 0
Thailand
State/province [49] 0 0
Chiang Mai
Country [50] 0 0
Thailand
State/province [50] 0 0
Songkla
Country [51] 0 0
United Kingdom
State/province [51] 0 0
Glasgow - Scotland
Country [52] 0 0
United Kingdom
State/province [52] 0 0
London
Country [53] 0 0
United Kingdom
State/province [53] 0 0
Plymouth

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Debiopharm International SA
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Novartis Pharmceuticals
Address 0 0
Novartis Pharmaceuticals
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

TypeCitations or Other Details
Journal Pawlotsky JM, Flisiak R, Sarin SK, Rasenack J, Pir... [More Details]

Results are available at https://clinicaltrials.gov/study/NCT01215643